The Danish Medicines Agency will examine its working processes to speed up approvals
This year, and over the next few years, new EU rules will come into force involving stricter requirements for case processing, among other things. To accomodate these, the Danish Medicines Agency will optimize its working processes so that businesses' contact with the agency becomes as smooth as possible.
It must be easier for pharmaceutical, medtech and biotech companies to contact and have their cases processed by the Danish Medicines Agency in the future.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
